• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Faraday Future Announces Chief Accounting Officer and Interim Chief Financial Officer, and Funding Progress

    10/26/22 9:31:00 PM ET
    $FFIE
    $IBRX
    $RMO
    Auto Manufacturing
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FFIE alert in real time by email

    - Yun Han named Chief Accounting Officer and Interim Chief Financial Officer -

    - Initial Funding Expected This Week Under $60 Million Financing Agreement -

    Faraday Future Intelligent Electric Inc. ("Faraday Future" or the "Company") (NASDAQ:FFIE), a California-based global shared intelligent electric mobility ecosystem company, today announced the appointment of Yun Han as Chief Accounting Officer and Interim Chief Financial Officer, effective October 25, 2022. Ms. Han replaces Becky Roof, who served as interim Chief Financial Officer until October 12, 2022, and is assisting the Company to ensure an orderly transition.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221026006161/en/

    Faraday Future today announced the appointment of Yun Han as Chief Accounting Officer and Interim Chief Financial Officer, effective October 25, 2022. (Photo: Business Wire)

    Faraday Future today announced the appointment of Yun Han as Chief Accounting Officer and Interim Chief Financial Officer, effective October 25, 2022. (Photo: Business Wire)

    Prior to joining Faraday Future, Ms. Han was Senior Vice President and Chief Accounting Officer at Romeo Power, Inc (NYSE:RMO). She was previously Vice President and Controller at Immunity Bio, Inc. (NASDAQ:IBRX), and held other senior accounting and finance positions at various companies. Earlier, she spent over 13 years with Price Waterhouse Coopers LLC's technical accounting and audit practice. She is a Certified Public Accountant licensed in the State of California and a graduate of the University of Southern California.

    "I am pleased to welcome Ms. Han as our Chief Accounting Officer and interim Chief Financial Officer. Yun's background, training, and industry experience make her ideally suited to join the leadership team at Faraday Future. I look forward to working closely with her to further strengthen our finance and accounting team, and to raise the additional funds required to deliver on our promise to bring the FF 91 to market as quickly as possible," said Dr. Carsten Breitfeld, Global CEO of Faraday Future.

    The Company also announced that it has received all of the previously announced $55 million financing (other than $5 million of additional bridge notes) from an affiliate of ATW Partners LLC as expected and anticipates receiving the first $10 million under the previously announced $60 million financing agreement this week. Certain additional proceeds are subject to the achievement of additional milestones and other factors as detailed in the Company's Form 8-K dated October 25, 2022. The Company filed a Form 8-K on October 26, 2022 which provides further information on the Company's current financial position.

    The Company continues to work diligently to raise the additional funds needed to fund its operations through the start of production, first deliveries, and beyond. "Faraday Future appreciates the effort of our largest shareholder FF Top Holdings LLC along with the exceptional work of my fellow board member Bob Ye, both of whom were instrumental in securing these new funds which bring us closer to delivering the FF 91," said Dr. Breitfeld. "Our factory is nearing completion, our car is meeting or exceeding performance specifications, and when we bring the FF 91 Futurist to market, we will reset consumer expectations for what an intelligent TechLuxury car should be," continued Dr. Breitfeld.

    Users can preorder an FF 91 Futurist via the FF Intelligent App or through our website (English): https://www.ff.com/us/preorder/ or (Chinese): https://www.ff.com/cn/preorder/

    Download the new FF Intelligent App (English): https://apps.apple.com/us/app/id1454187098 or https://play.google.com/store/apps/details?id=com.faradayfuture.online, (Chinese): http://appdownload.ff.com

    ABOUT FARADAY FUTURE

    Faraday Future is a class defining luxury electric vehicle company. The Company has pioneered numerous innovations relating to its products, technology, business model, and user ecosystem since inception in 2014. Faraday Future aims to perpetually improve the way people move by creating a forward-thinking mobility ecosystem that integrates clean energy, AI, the Internet and new usership models. Faraday Future's first flagship product is the FF 91 Futurist.

    FOLLOW FARADAY FUTURE:

    https://www.ff.com/

    http://appdownload.ff.com

    https://twitter.com/FaradayFuture

    https://www.facebook.com/faradayfuture/

    https://www.instagram.com/faradayfuture/

    www.linkedin.com/company/faradayfuture

    NO OFFER OR SOLICITATION

    This communication shall neither constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

    FORWARD LOOKING STATEMENTS

    This press release includes "forward looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include the Company's ability to satisfy the conditions precedent and close on the various financings previously disclosed by the Company, the failure of any which could result in the Company seeking protection under the Bankruptcy Code; the satisfaction of the conditions to the advance approval by FF Top and Season Smart Limited of the warrants and notes issued to affiliates of ATW Partners LLC and Daguan International Limited; the ability of the Company to agree on definitive documents to effectuate the governance changes with FF Top; the Company's ability to remain in compliance with its public filing requirements under the Securities Exchange Act of 1934, as amended, and the listing requirements of The Nasdaq Stock Market LLC ("Nasdaq") and to continue to be listed on Nasdaq; the outcome of the SEC investigation relating to the matters that were the subject of the Special Committee investigation; the Company's ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company's estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company's vehicles; the success of other competing manufacturers; the performance and security of the Company's vehicles; potential litigation involving the Company; the result of future financing efforts and general economic and market conditions impacting demand for the Company's products; recent cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; and the ability of the Company to attract and retain employees, including a replacement auditor. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of the Company's registration statement on Form S-1/A filed on October 7, 2022, and other documents filed by the Company from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221026006161/en/

    Get the next $FFIE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FFIE
    $IBRX
    $RMO

    CompanyDatePrice TargetRatingAnalyst
    ImmunityBio Inc.
    $IBRX
    3/6/2025$8.00Buy
    H.C. Wainwright
    ImmunityBio Inc.
    $IBRX
    1/10/2025$6.00Buy
    BTIG Research
    ImmunityBio Inc.
    $IBRX
    5/12/2023$10.00 → $4.00Overweight → Neutral
    Piper Sandler
    Faraday Future Intelligent Electric Inc.
    $FFIE
    8/16/2022Buy → Hold
    The Benchmark Company
    ImmunityBio Inc.
    $IBRX
    8/3/2022$8.00Buy
    Jefferies
    Romeo Power Inc.
    $RMO
    3/2/2022Buy → Neutral
    BTIG
    Faraday Future Intelligent Electric Inc.
    $FFIE
    11/16/2021$17.00 → $10.00Outperform → Neutral
    Wedbush
    Romeo Power Inc.
    $RMO
    10/27/2021$4.00Outperform → Market Perform
    Cowen
    More analyst ratings

    $FFIE
    $IBRX
    $RMO
    SEC Filings

    See more
    • ImmunityBio Inc. filed SEC Form 8-K: Other Events

      8-K - ImmunityBio, Inc. (0001326110) (Filer)

      5/5/25 7:15:22 AM ET
      $IBRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by ImmunityBio Inc.

      DEFA14A - ImmunityBio, Inc. (0001326110) (Filer)

      4/29/25 6:48:43 PM ET
      $IBRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by ImmunityBio Inc.

      DEF 14A - ImmunityBio, Inc. (0001326110) (Filer)

      4/29/25 6:22:43 PM ET
      $IBRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FFIE
    $IBRX
    $RMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Faraday Future Intelligent Electric Inc.

      SC 13G/A - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Subject)

      11/14/24 4:56:24 PM ET
      $FFIE
      Auto Manufacturing
      Consumer Discretionary
    • SEC Form SC 13G filed by Faraday Future Intelligent Electric Inc.

      SC 13G - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Subject)

      10/8/24 8:03:22 PM ET
      $FFIE
      Auto Manufacturing
      Consumer Discretionary
    • SEC Form SC 13G filed by Faraday Future Intelligent Electric Inc.

      SC 13G - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Subject)

      9/16/24 7:35:11 PM ET
      $FFIE
      Auto Manufacturing
      Consumer Discretionary

    $FFIE
    $IBRX
    $RMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Global Chief Executive Officer Aydt Matthias disposed of $100 worth of Series A Preferred Stock (1 units at $100.00), decreasing direct ownership by 50% to 1 units (SEC Form 4)

      4 - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Issuer)

      3/11/25 4:26:38 PM ET
      $FFIE
      Auto Manufacturing
      Consumer Discretionary
    • Chief Accounting Officer Lauer Regan J converted options into 4,065 shares and covered exercise/tax liability with 1,669 shares, increasing direct ownership by 2% to 110,258 units (SEC Form 4)

      4 - ImmunityBio, Inc. (0001326110) (Issuer)

      2/25/25 9:11:45 PM ET
      $IBRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Soon-Shiong Patrick covered exercise/tax liability with 42,071 shares and converted options into 114,329 shares, increasing direct ownership by 0.25% to 29,546,190 units (SEC Form 4)

      4 - ImmunityBio, Inc. (0001326110) (Issuer)

      2/25/25 9:11:37 PM ET
      $IBRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FFIE
    $IBRX
    $RMO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $FFIE
    $IBRX
    $RMO
    Leadership Updates

    Live Leadership Updates

    See more
    • ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

      ImmunityBio, Inc. ((IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for the indication of papillary disease. This RTF letter was received despite reaching unanimous guidance and encouragement at the in-person January 2025 meeting from the leadership of the Agency, including from CBER, CDER and OCE to submit this sBLA. At this meeting all key decision makers were specifically asked and unanimously confirmed

      5/5/25 6:30:00 AM ET
      $IBRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

      CIS with or without Papillary: Oral presentation from QUILT-3.032 study showed 71% complete response rate (N=100), with duration of response ranging up to more than 53 months, in BCG-unresponsive NMIBC CIS with or without papillary disease Probability of duration of complete response of at least 45 months in the FDA label population (N=77) is 51%, with median duration of complete response of 45.4 months Cystectomy avoidance rate in responders of 84% at 36 months Disease-specific overall survival rate of 99% at 36 months Longest follow-up of BCG-unresponsive CIS patients with unmatched more than 5 years data available (as of July 2024 data cutoff) Papillary without CIS: Disease

      4/28/25 8:30:00 AM ET
      $IBRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

      Oral presentation provides update from QUILT-3.032 on durable complete responses to ANKTIVA® plus BCG in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) with or without Ta/T1 papillary disease and papillary disease alone ImmunityBio to present keynote events on NMIBC and experience in prostate cancer, unveiling lymphopenia, the Absolute Lymphocyte Count (ALC) biomarker for all tumor types, and the ‘Cancer BioShield' Supplemental Biologics License Application for BCG unresponsive NMIBC for papillary disease alone submitted to the FDA Updates to be provided on status of Expanded Access Authorization of ANKTIVA as a BioShield ImmunityBio, Inc. ((IBRX)

      4/21/25 4:21:00 PM ET
      $IBRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Faraday Future Appoints Tommy Zhao as Senior Director of FF Par Sales and After-Sales to Help Drive Future FF and FX Sales

      Mr. Zhao will be responsible for leading FF's Par Sales and After-Sales department and functions. Mr. Zhao's career experience includes both consulting roles as well as numerous automotive-focused executive leadership roles, including VP of Sales, Commercial Strategy & Special Vehicle Operations, focused on Jaguar Land Rover in China and a host of premium retail experiences in the luxury segment including Porsche. Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) ("FF," "Faraday Future," or the "Company"), a California-based global intelligent electric mobility company, today announced the appointment of Tommy Zhao as Senior Director of FF Par Sales and After-Sales. This press

      2/4/25 8:57:00 PM ET
      $FFIE
      Auto Manufacturing
      Consumer Discretionary
    • Faraday Future to Empower Strategic Growth through Key Proposals at Next Extraordinary General Meeting

      Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) ("Faraday Future" or the "Company"), a California-based global shared intelligent electric mobility ecosystem company, today announced plans to host an Extraordinary General Meeting of Stockholders (the "EGM") on March 7, 2025, to seek approval for proposals aimed at supporting the Company's strategic initiatives and long-term growth. The Company urges all stockholders to vote FOR all proposals. Proposal Highlights Share Authorization Proposal Approval of an amendment to the Company's Charter to increase the number of authorized shares of Common Stock by 25,000,000, from 104,245,313 to 129,245,313, representing a 24% increase. Thi

      1/31/25 7:00:00 AM ET
      $FFIE
      Auto Manufacturing
      Consumer Discretionary
    • Faraday Future Announces FX's First Class AI-MPV Product Strategy and Planned Product—FX Super One, Giving FX Business Strategy Updates From Las Vegas

      FX camouflaged prototype mules shown for the first time to the public in Las Vegas, NV, as the Company outlined its product development and U.S. regulatory testing phase for the FX product lineup. The first planned FX models include the first U.S. AI-MPV product—the Super One, the FX 5 (expected price range of $20,000-$30,000), and FX 6 (expected price range of $30,000-$50,000), which could offer two types of powertrains: range-extended AIEV and battery-electric AIEV, with a targeted initial roll-off the line for at least one model by the end of 2025. The Company also showed a teaser shot of the FX 6 prototype mule, with an update planned for March 2025. In Q2 of this year, the Co

      1/8/25 8:00:00 PM ET
      $FFIE
      Auto Manufacturing
      Consumer Discretionary

    $FFIE
    $IBRX
    $RMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on ImmunityBio with a new price target

      H.C. Wainwright initiated coverage of ImmunityBio with a rating of Buy and set a new price target of $8.00

      3/6/25 7:26:14 AM ET
      $IBRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BTIG Research initiated coverage on ImmunityBio with a new price target

      BTIG Research initiated coverage of ImmunityBio with a rating of Buy and set a new price target of $6.00

      1/10/25 8:13:47 AM ET
      $IBRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ImmunityBio downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded ImmunityBio from Overweight to Neutral and set a new price target of $4.00 from $10.00 previously

      5/12/23 7:19:52 AM ET
      $IBRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FFIE
    $IBRX
    $RMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Global Chief Executive Officer Aydt Matthias bought $100 worth of Series A Preferred Stock (1 units at $100.00) (SEC Form 4)

      4 - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Issuer)

      1/30/25 9:36:52 PM ET
      $FFIE
      Auto Manufacturing
      Consumer Discretionary
    • Global Chief Exec. Officer Aydt Matthias disposed of $100 worth of Series A Preferred Stock (1 units at $100.00) and bought $100 worth of Series A Preferred Stock (1 units at $100.00), decreasing direct ownership by 50% to 1 units (SEC Form 4)

      4 - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Issuer)

      6/25/24 4:11:43 PM ET
      $FFIE
      Auto Manufacturing
      Consumer Discretionary
    • Aydt Matthias bought $100 worth of Series A Preferred Stock (1 units at $100.00) (SEC Form 4)

      4 - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Issuer)

      12/27/23 5:23:13 PM ET
      $FFIE
      Auto Manufacturing
      Consumer Discretionary

    $FFIE
    $IBRX
    $RMO
    Financials

    Live finance-specific insights

    See more
    • ImmunityBio Reports Third-Quarter 2024 Financial Results

      ImmunityBio, Inc. ((IBRX) today announced its financial results for the third-quarter ended September 30, 2024. ANKTIVA® received a J-code (HCPCS Level II Code) in October 2024, effective January 1, 2025. ANKTIVA (FDA-approved and commercially available in the U.S. since May 2024) is now widely accessible to patients through commercial and government insurance programs (VA, DoD, Medicare). ImmunityBio has secured coverage for over 200 million medical lives through medical reimbursement policies. ImmunityBio achieved a net product revenue of approximately $6.0 million during the three months ended September 30, 2024, surpassing net product revenue of $1.0 million in the prior quarte

      11/12/24 7:15:00 AM ET
      $IBRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Faraday Future Reports Financial Results for Third Quarter 2024

      Strategic FX Second Brand Launch, Completion of Strategic Realignment, and Significant Middle East Expansion Mark Transformative Quarter. Successfully Secured and Closed on $30 Million Financing. Regained Full Nasdaq Compliance. FX Brand Launch Targets Mass Market with Models Targeted in $20,000-$50,000 Range with Potential Roll Off the Assembly Line by the End of 2025, Subject to Securing Necessary Funding. FX Project in First Phase of Vehicle Development, With Related Work Underway to Achieve Phase One Milestones. FX Plans to Announce Progress and Next Steps Execution Plan Next Week. Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) ("FF", "Faraday Future", or the "Company

      11/6/24 4:45:00 PM ET
      $FFIE
      Auto Manufacturing
      Consumer Discretionary
    • Faraday Future Announces Third Quarter 2024 Earnings and Webcast Timing

      Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) ("Faraday Future," "FF," or the "Company"), a California-based global shared intelligent electric mobility ecosystem company, today announced that it is scheduled to have a conference call on its third quarter results for 2024 after market close on Wednesday, November 6, 2024, at 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time). Interested investors and other parties can listen to a webcast of the conference call by logging onto the Investor Relations section of the Company's website at https://investors.ff.com/. A replay of the webcast will be available on the Company's website shortly thereafter. ABOUT FARADAY FUTURE Faraday Future

      10/31/24 10:15:00 PM ET
      $FFIE
      Auto Manufacturing
      Consumer Discretionary